Trial Profile
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms COSTAN
- Sponsors Biogen
- 26 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 22 Feb 2015 Modified the official title, inclusion and exclusion criteria as per ClinicalTrials.gov record.
- 07 Nov 2012 New trial record